Medtronic says this is the first stent of this kind that carries an indication for use with diabetes patients with coronary artery disease. In a communiqué issued by Medtronic, Martin B. Leon, M.D. , principal investigator (PI) of the RESOLUTE US...

Devices that the Senators want to know about the "financial relationships" between paid researchers who glossed over the side effects of Infuse--side effects that include incapacitating swelling in the throat that have caused permanent injury and even...

The program, which started in the summer of 2010, seeks to help local start-ups become well-established names, with the broader goal of creating jobs in the state. "If one or two of those [113 firms] in 20 years is a Medtronic or 3M, with tens of...

Ellis also spelled out the opportunity that Resolute represents domestically: To put the U.S. opportunity in perspective, in Europe, where Resolute is approved and we have more competitors than in the U.S. , our DES share is nearly double our U.S. share.

Inc. completed enrollment in one of its U.S. clinical trials for the CoreValve device last month. A Marketplace article Friday about the launch of a rival heart-valve device incorrectly indicated CoreValve had completed enrollment in all U.S. trials. ...

The FDA has approved the Resolute zotarolimus-eluting stent for the treatment of coronary artery disease. The Resolute DES is approved for use in a wide variety of patients, including diabetics. The new stent??uses the same drug-and-polymer combination...